Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Marker Therapeutics to receive two grants ... confident in seeing additional responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and tells investors ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Instead of extracting T-cells and engineering them in a lab, researchers have delivered mRNA directly into circulating immune ...

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

Genetic markers are DNA sequences with known physical locations on chromosomes. They are points of variation that can be used to identify individuals or species, or may be used to associate an ...

The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleared the new indication ...